Janine Michel

Dr. Janine Michel

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JOJames R. Otieno
James R. Otieno
CRChristopher Ruis
Christopher Ruis
AOAnyebe Bernard Onoja
Anyebe Bernard Onoja
KKKrutika Kuppalli
Krutika Kuppalli
AHAna Hoxha
Ana Hoxha
LSLorenzo Subissi
Lorenzo Subissi
Monkeypox virus (MPXV) is endemic in western and Central Africa, and in May 2022, a clade IIb lineage (B.1) caused a global outbreak outside Africa, resulting in its detection in 116 countries and territories. To understand the global phylogenetics of MPXV, we analyzed all available MPXV sequences, including 10,670 sequences from 65 countries collected between 1958 and 2024. Our analysis reveals high mobility of clade I viruses within Central Africa, sustained human-to-human transmission of clade IIb lineage A viruses within the Eastern Mediterranean region and distinct mutational signatures that can distinguish sustained human-to-human from animal-to-animal transmission. Moreover, distinct clade I sequences from Sudan suggest local MPXV circulation in areas of eastern Africa over the past four decades. Our study underscores the importance of genomic surveillance in tracking spatiotemporal dynamics of MXPV clades and the need to strengthen such surveillance, including in some parts of eastern Africa.

11 November 2022 in Eurosurveillance
Verified
Journal Article
Open access
JMJanine Michel
Janine Michel
ATAngelina Targosz
Angelina Targosz
TRThomas Rinner
Thomas Rinner
DBDaniel Bourquain
Daniel Bourquain
ABAnnika Brinkmann
Annika Brinkmann
ANAndreas Nitsche
Andreas Nitsche
Before the international spread of monkeypox in May 2022, PCR kits for the detection of orthopoxviruses, and specifically monkeypox virus, were rarely available. Here we describe the evaluation of 11 recently developed commercially available PCR kits for the detection of monkeypox virus DNA. All tested kits are currently intended for research use only and clinical performance still needs to be assessed in more detail, but all were suitable for diagnostics of monkeypox virus, with variations in specificity rather than sensitivity.

18 June 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
KZKhaoula Zouaghi
Khaoula Zouaghi
ABAli Bouattour
Ali Bouattour
HAHajer Aounallah
Hajer Aounallah
RSRebecca Surtees
Rebecca Surtees
EKEva Krause
Eva Krause
YMYoumna M'ghirbi
Youmna M'ghirbi
Crimean-Congo hemorrhagic fever virus (CCHFV, Nairoviridae family) and Rift Valley fever virus (RVFV, Phenuiviridae family) are zoonotic vector-borne pathogens with clinical relevance worldwide. Our study aimed to determine seroprevalences of these viruses and potential risk factors among livestock (cattle, sheep, and goats) in Tunisia. Sera were tested for antibodies against CCHFV (n = 879) and RVFV (n = 699) using various enzyme-linked immunosorbent assays (ELISAs) and indirect immunofluorescence assays (IIFA). The overall seroprevalence of IgG antibodies was 8.6% (76/879) and 2.3% (16/699) against CCHFV and RVFV, respectively. For CCHF seropositivity bioclimatic zones and breed were potential risk factors for the three tested animal species; while the season was associated with cattle and sheep seropositivity, tick infestation was associated with cattle and goats seropositivity and age as a risk factor was only associated with cattle seropositivity. Age and season were significantly associated with RVFV seropositivity in sheep. Our results confirm the circulation of CCHFV and RVFV in Tunisia and identified the principal risk factors in ruminants. This knowledge could help to mitigate the risk of ruminant infections and subsequently also human infections.

13 March 2023 in Infection
Verified
Journal Article
Open access
PDF file
ASAnna Stoliaroff-Pepin
Anna Stoliaroff-Pepin
CPCaroline Peine
Caroline Peine
THTim Herath
Tim Herath
JLJohannes Lachmann
Johannes Lachmann
WHWiebke Hellenbrand
Wiebke Hellenbrand
THThomas Harder
Thomas Harder
Purpose: COViK, a prospective hospital-based multicenter case-control study in Germany, aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we report vaccine effectiveness (VE) against COVID-19-caused hospitalization and intensive care treatment during the Omicron wave. Methods: We analyzed data from 276 cases with COVID-19 and 494 control patients recruited in 13 hospitals from 1 December 2021 to 5 September 2022. We calculated crude and confounder-adjusted VE estimates. Results: 21% of cases (57/276) were not vaccinated, compared to 5% of controls (26/494; p < 0.001). Confounder-adjusted VE against COVID-19-caused hospitalization was 55.4% (95% CI: 12–78%), 81.5% (95% CI: 68–90%) and 95.6% (95%CI: 88–99%) after two, three and four vaccine doses, respectively. VE against hospitalization due to COVID-19 remained stable up to one year after three vaccine doses. Conclusion: Three vaccine doses remained highly effective in preventing severe disease and this protection was sustained; a fourth dose further increased protection.

9 March 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ABAnnika Brinkmann
Annika Brinkmann
SUSteven Uddin
Steven Uddin
SUSophie-Luisa Ulm
Sophie-Luisa Ulm
KPKatharina Pape
Katharina Pape
SFSophie Förster
Sophie Förster
ANAndreas Nitsche
Andreas Nitsche
Since December 2019 the world has been facing the outbreak of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Identification of infected patients and discrimination from other respiratory infections have so far been accomplished by using highly specific real-time PCRs. Here we present a rapid multiplex approach (RespiCoV), combining highly multiplexed PCRs and MinION sequencing suitable for the simultaneous screening for 41 viral and five bacterial agents related to respiratory tract infections, including the human coronaviruses NL63, HKU1, OC43, 229E, Middle East respiratory syndrome coronavirus, SARS-CoV, and SARS-CoV-2. RespiCoV was applied to 150 patient samples with suspected SARS-CoV-2 infection and compared with specific real-time PCR. Additionally, several respiratory tract pathogens were identified in samples tested positive or negative for SARS-CoV-2. Finally, RespiCoV was experimentally compared to the commercial RespiFinder 2SMART multiplex screening assay (PathoFinder, The Netherlands).

1 August 2021 in Molecular and Cellular Probes
Verified
Journal Article
Open access
EKEva Krause
Eva Krause
APAndreas Puyskens
Andreas Puyskens
DBDaniel Bourquain 
Daniel Bourquain 
ABAnnika Brinkmann
Annika Brinkmann
BBBarbara Biere
Barbara Biere
ANAndreas Nitsche
Andreas Nitsche
Point of care detection of SARS-CoV-2 is one pillar in a containment strategy and important to break infection chains. Here we report the sensitive, specific and robust detection of SARS-CoV-2 and respective variants of concern by the ID NOW COVID-19 device.